Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 16.98M P/E - EPS this Y 26.60% Ern Qtrly Grth -
Income -6.93M Forward P/E -0.45 EPS next Y 10.20% 50D Avg Chg -3.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 1.84 EPS next 5Y - 52W High Chg -71.00%
Recommedations 2.00 Quick Ratio 1.10 Shares Outstanding 3.25M 52W Low Chg 9.00%
Insider Own 34.64% ROA -71.52% Shares Float 2.31M Beta 0.80
Inst Own 11.87% ROE -129.29% Shares Shorted/Prior 16.77K/16.14K Price 0.83
Gross Margin - Profit Margin - Avg. Volume 59,566 Target Price 20.50
Oper. Margin - Earnings Date Dec 13 Volume 31,751 Change -0.27%
About Edesa Biotech, Inc.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
van der Velden Peter 10% Owner 10% Owner Jan 09 Sell 2.65 297,474 788,306 150,275 01/11/23
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Jun 30 Buy 1.6039 20,000 32,078 594,812 07/05/22
Brooks Michael J President President Jun 29 Buy 1.4943 3,000 4,483 26,241 06/30/22
Brooks Michael J President President Jun 16 Buy 1.6055 3,000 4,816 23,241 06/21/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer May 27 Buy 1.9198 5,000 9,599 574,812 05/31/22
Brooks Michael J President President May 25 Buy 1.74 3,500 6,090 20,241 05/26/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer May 24 Buy 1.7998 2,000 3,600 569,812 05/25/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 31 Buy 2.9858 2,000 5,972 567,812 04/01/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 30 Buy 3.0491 2,000 6,098 565,812 03/31/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 29 Buy 3.0168 2,000 6,034 563,812 03/30/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 18 Buy 3.8496 2,000 7,699 561,812 03/21/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 17 Buy 3.26 2,000 6,520 559,812 03/18/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 15 Buy 2.799 2,000 5,598 557,812 03/16/22
Brooks Michael J President President Mar 14 Buy 2.7893 1,250 3,487 16,741 03/15/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 11 Buy 3.12 7,000 21,840 555,812 03/14/22
Brooks Michael J President President Mar 10 Buy 3.2229 1,000 3,223 15,491 03/11/22
Nijhawan Pardeep Chief Executive Offi.. Chief Executive Officer Mar 09 Buy 3.0464 1,500 4,570 548,812 03/10/22
Brooks Michael J President President Mar 08 Buy 2.8975 1,250 3,622 14,491 03/09/22